RECOVERY & TISSUE REPAIR / FAQ
Questions From the Research Record
Direct answers to the questions most often asked about these three tissue-repair peptides, anchored to citations.
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide (glycyl-histidyl-lysine plus a copper ion) that occurs naturally in the body and drives collagen, elastin, and glycosaminoglycan synthesis in skin. At the gene level, it shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold, largely toward wound-repair, antioxidant, and DNA-repair programs [2]. Topically, as Copper Tripeptide-1, it is a legal cosmetic ingredient; it is not an approved medicine for injection or other systemic use.
What is GHK-Cu and how does it work?
GHK-Cu is the tripeptide Gly-His-Lys chelated to a copper(II) ion, occurring naturally in human plasma and declining from roughly 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 [4]. It works by directly stimulating dermal fibroblasts to synthesize collagen, elastin, and decorin, and by enabling copper-dependent cross-linking of collagen and elastin fibers via the enzyme lysyl oxidase. Most documented activity is topical; injectable or systemic use is unapproved and has no established human pharmacokinetic data.
Is GHK-Cu peptide really anti-aging?
The evidence supports a real, but narrow and mostly topical, anti-aging effect. A review found topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid [1][4]. The main practical limitation is delivery: native GHK penetrates the skin poorly, which is why newer formulations — palmitoylated GHK, microneedle-assisted delivery — are being studied as enhancements [1]. The broader anti-aging narrative around GHK-Cu also draws on gene-expression and rodent data that has not all been confirmed in controlled human trials.
What is the difference between GHK and GHK-Cu?
GHK is the plain tripeptide (glycine-histidine-lysine) without any metal bound to it. GHK-Cu is the same tripeptide chelated to a copper(II) ion. The distinction matters because copper coordination is required for much of the peptide's documented activity — cell studies show the copper-free form does not reproduce key effects, such as stimulating matrix metalloproteinases, that the copper-bound complex does. Most of the published research, including the findings on this site, describes the copper-bound GHK-Cu complex specifically.
What is TB-500?
TB-500 is a synthetic, seven-amino-acid peptide (Ac-LKKTETQ) built to match residues 17-23 of the much larger, naturally occurring protein thymosin beta-4. It is not approved for any human use and is prohibited in competitive sport by the World Anti-Doping Agency [8]. No completed controlled human trial has tested the TB-500 fragment itself — the one human safety study in this research area used the full-length parent protein instead [11].
What does TB-500 stand for and what does TB stand for in TB-500?
'TB' refers to thymosin beta — the protein family TB-500 is derived from, specifically thymosin beta-4. 'TB-500' itself is not an official chemical name; it is a research-community designation for the synthetic Ac-LKKTETQ fragment corresponding to thymosin beta-4's actin-binding region, residues 17-23 [10][12].
What is TB-500 used for in research?
In preclinical research, TB-500 and its parent protein are studied for tissue-injury recovery: cell migration, angiogenesis, reduced scar (myofibroblast) formation, and anti-inflammatory signaling after injury [10]. A rat stroke model found neurological improvement at moderate doses of the full-length protein but not at the highest dose tested, a non-monotonic result [9]. There is no approved human therapeutic use, and this page does not describe a research application as a basis for human use.
Does TB-500 work for muscle tears and recovery from exercise?
There is no completed controlled human trial testing TB-500 for muscle tears or exercise recovery. The evidence that exists — largely from full-length thymosin beta-4 in rodent injury models — supports a plausible mechanism (actin-mediated cell migration, reduced scarring, angiogenesis) [10], but a 2026 review of unapproved musculoskeletal peptides concluded that human safety data for this category remain scarce and that any efficacy signal is currently limited to animal models [8]. Reports of faster recovery from tendon and muscle injuries are common in research-use communities but are anecdotal, not clinical evidence.
What is the Wolverine peptide blend?
Wolverine is a research-community name for combining two separate peptides — BPC-157 and TB-500 — in one protocol, aimed at tissue and injury recovery. It is not a single chemical entity, has no unique molecular structure of its own, and has never been studied as a combination in any published trial [13][14].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence found in human gastric juice, studied mainly in animal models for angiogenic and cytoprotective effects via the VEGFR2 pathway [15]. TB-500 is the synthetic Ac-LKKTETQ fragment of thymosin beta-4, reasoned to regulate cell migration through actin binding [10][12]. They are structurally unrelated peptides that happen to be marketed together.
What is the BPC-157 and TB-500 blend used for in research?
In research-use communities, the blend is used with the goal of tissue and injury recovery — tendon, ligament, and muscle healing in particular. The rationale is that BPC-157 supplies a local, vascular and cytoprotective signal [15] while TB-500 supplies an intracellular, cell-migration signal [10], theoretically covering more of the repair process than either alone. No published study has tested this combined rationale; a 2025 systematic review of BPC-157 explicitly found no human safety data and made no mention of TB-500 or combination protocols [13].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The two are combined because their proposed mechanisms are largely non-overlapping: BPC-157 acts through an angiogenic, VEGFR2-driven pathway [15], while TB-500 acts through an intracellular, actin-based cell-migration pathway tied to its parent protein, thymosin beta-4 [10]. The reasoning is that pairing two different mechanisms could address more of the repair process than either peptide alone. This is a mechanistic hypothesis, not a tested finding — no controlled study has measured the two given together, and a 2025 narrative review found human data even for BPC-157 alone limited to three pilot studies [14].